GL Pharm Tech Corp. (KOSDAQ: 204840)

Market Cap	82.09B
Revenue (ttm)	27.91B
Net Income (ttm)	-4.26B
Shares Out	76.87M
EPS (ttm)	-63.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,482
Open	1,075.00
Previous Close	1,075.00
Day's Range	1,070.00 - 1,097.00
52-Week Range	730.00 - 1,830.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 204840

Financial Performance

In 2023, GL Pharm Tech's revenue was 26.03 billion, an increase of 55.62% compared to the previous year's 16.73 billion. Losses were -3.75 billion, 374.4% more than in 2022.